Huahui healthcare
Web31 jan. 2024 · Huahui Health Study record dates These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website. Study Major … Web21 aug. 2024 · Huahui Health Announces Late-Breaking Data for Its Investigational Anti-PreS1 HBV Neutralizing Antibody at the AASLD 2024. View details; 2024-10-28. HH … Prior to Huahui Health, Dr. Ye played multiple leading roles during drug … HH-003 is a novel entry inhibitor for HBV & HDV. It has the potential to become a … Huahui Health Announces Late-Breaking Data for Its Investigational Anti-PreS1 … Huahui Health Ltd. and its affiliates are the controllers of your personal information. … Tel:010-80766688 Email: [email protected]. Floor 7-8, Building 5, No.9 Yike Road, … Tel:010-80766688 Email: [email protected]. Floor 7-8, Building 5, No.9 Yike Road, … 2024-11-08. 华辉安健在研乙肝新药hh-003在美国肝病研究学会2024年会上公 …
Huahui healthcare
Did you know?
Web6 mei 2024 · Huahui Health (Hong Kong) Co., Limited (華輝安健 (香港)有限公司) was incorporated on 06-MAY-2024 as a private company limited by shares type, The date of annual examination for this private company limited is between May 06 and Jun 16 upon the anniversary of incorporation. The company status is Live now. Web11 nov. 2024 · HH-120 is a novel inhalable biologic being developed for COVID-19 treatment. The study aims to evaluate the safety, tolerability and pharmacokinetic profile …
WebHealth management and winning practice articles, value-based healthcare, healthcare events, company and product directory, I-I-I videos and I-I-I blog interviews. User … Web6 feb. 2024 · Huahui Health Investigators None specified. Study Documents (Full-Text) None provided. More Information Publications None provided. Responsible Party: Huahui Health ClinicalTrials.gov Identifier: NCT05713318 Other Study ID Numbers: HH120-NS215 First Posted: Feb 6, 2024 Last Update Posted: Feb 6, 2024 Last Verified: Feb 1, 2024
Web11 sep. 2024 · September 14, 2024 updated by: Huahui Health. A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple-dose HH-003 Injection in Treatment Naïve Participants With HBeAg-positive Chronic HBV Infection. Web11 mrt. 2024 · Huahui Health is developing a treatment for Hepatitis B virus. This study is designed to evaluate the safety and tolerability of HH-006, a hepatitis virus neutralizing monoclonal antibody in healthy volunteers, and to determine its pharmacokinetic profile and immunogenicity. Detailed Description:
WebLegal Name Huahui Health Ltd. Company Type For Profit Contact Email [email protected] Phone Number 010-80766688 Huahui Health engages in the R&D of innovative drugs for digestive diseases such as hepatitis B, liver cancer, and pancreatic cancer. It has developed novel drug candidates for hepatitis B to achieve the ambitious goal of a functional cure.
WebHUAWEI Health is your go-to, integrated health and fitness companion. Kick-start your fitness life, keep track of your health, or conveniently manage your smart wearable devices, HUAWEI Heath App has what you're going for. bob farndon artistWeb30 dec. 2024 · 2024年12月30日上午，北京中关村生命科学园发展有限责任公司与华辉安健（北京）生物科技有限公司合作共建的医药科技中心5号楼装修改造工程开工仪式如期举行。生命园管委会主任靳浥、昌发展副总王彧、生命园公司总经理王文礼、华辉安健共同创始人李文辉、中国电子系统工程第二建设有限公司 ... bob farnon tyresWeb15 mrt. 2024 · Huahui Health General Information Description Developer of antibody treatments for Hepatitis intended to improve the quality of life for patients suffering from … bob farnsworth gray gaWeb8 jan. 2024 · Latest HUAHUI HEALTH LTD. Patents: Anti-pre-S1 HBV antibodies A METHOD OF TREATING HBV INFECTION BY USING ANTI-PRE-S1 HBV ANTIBODIES ANTI-FGF19 ANTIBODIES POLYMERIC BILE ACID DERIVATIVES INHIBIT HEPATITIS B AND D VIRUS AND NTCP TRANSPORT Skip to:Description · Claims · References … clip art for painWeb28 mrt. 2024 · Huahui Health: ClinicalTrials.gov Identifier: NCT05787418 Other Study ID Numbers: HH120-NS311 : First Posted: March 28, 2024 Key Record Dates: Last Update Posted: March 28, 2024 Last Verified: March 2024 Layout table for additional information; Studies a U.S. FDA-regulated Drug ... bob farnonWebLegal Name Huahui Health Ltd. Company Type For Profit Contact Email [email protected] Phone Number 010-80766688 Huahui Health engages in the R&D of innovative drugs … clip art for outlook signatureWeb2 mrt. 2024 · Huahui Health is developing a treatment for Hepatitis B virus. This study is designed to evaluate the safety and tolerability of HH-006, a hepatitis virus neutralizing … bob farquharson case knives